Eli Lilly and Company: Skin Diseases trials
The registry lists 11 Skin Diseases studies with Eli Lilly and Company as lead sponsor. 1 are open to participants now and 9 have results posted.
Phase 1 1Phase 2 1Phase 3 9(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia AreataRecruitingNCT05723198Phase 3
- A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic DermatitisCompletedNCT04760314Phase 3Results posted
- A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)CompletedNCT04626297Phase 3Results posted
- Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)CompletedNCT04392154Phase 3Results posted
- Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic DermatitisCompletedNCT04250350Phase 3Results posted
- Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.CompletedNCT04250337Phase 3Results posted
- Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic DermatitisCompletedNCT04178967Phase 3Results posted
- Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)CompletedNCT04146363Phase 3Results posted
- A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque PsoriasisCompletedNCT03364309Phase 3Results posted
- A Phase 2b Study of Baricitinib in Participants With Moderate to Severe PsoriasisCompletedNCT01490632Phase 2Results posted
- A Study of LY3041658 in Participants With Skin DiseasesCompletedNCT02896868Phase 1